Credit score: Markus Winkler from Pexels
Danish pharmaceutical large Novo Nordisk, maker of diabetes and weight-loss remedies Ozempic and Wegovy, mentioned Monday it was investing 8.5 billion kroner ($1.2 billion) to construct a brand new manufacturing unit in Denmark to provide medicine in opposition to uncommon ailments.
The 40,000-square-meter (430,000-square-feet) manufacturing facility and warehouse in Odense “marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site,” the corporate mentioned in an announcement.
“Designed to be modular and flexible, it will accommodate multiple product types within rare disease, such as hemophilia, both now and in the future,” Novo Nordisk mentioned.
Henrik Wulff, government vice chairman at Novo Nordisk, mentioned the power would assist the corporate “meet the growing global demand for our life-changing medicines”.
In November, the drugmaker posted a 21-percent rise in web revenue to 27.3 billion kroner ($3.85 billion) for the July-to-September interval, however lamented capability limitations at its manufacturing websites.
Novo Nordisk mentioned that building work on the Odense website had commenced and it’s scheduled to be accomplished in 2027.
It’s anticipated to create 400 jobs as soon as accomplished.
Gross sales of Wegovy, which has been permitted to be used to deal with weight problems in Britain, Denmark, France, Germany, Norway and america, rose by 42 % within the first 9 months of the 12 months, in response to Novo Nordisk.
Gross sales of the corporate’s different semiglutide bestseller, Ozempic—an injectable anti-diabetic therapy which has turn out to be widespread for its slimming properties—soared by 54 % in the identical interval.
Novo Nordisk has a maintain on 74 % of the marketplace for weight-loss remedies.
The World Weight problems Federation predicts that by 2035, over half of the world’s inhabitants can be obese or overweight and the worldwide financial affect might then exceed $4 trillion a 12 months.
© 2024 AFP
Quotation:
Weight-loss drugmaker Novo Nordisk invests $1.2 bn in new manufacturing unit in Denmark (2024, December 16)
retrieved 16 December 2024
from https://medicalxpress.com/information/2024-12-weight-loss-drugmaker-novo-nordisk.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
